Combined archive search across FBI Vault, SPLC, PHMPT, ACIP, NIH grants, the Federal Writers' Project, and other collections we've ingested.
Brian O'Shea · RAGIN' CAJUN FACILITIES, INC. · 2023 · $3,999,070 — University of Louisiana at Lafayette C06 Expansion of Macaque Breeding capacity at the New Iberia Research Center Abstract: As part of its expansion of its HIV/AIDS research program, the New Iberia Research Center (NIRC) at the University of Louisiana at Lafayette (UL Lafayette) proposes to add maca…
Daniel S Chertow · CLINICAL CENTER · 2023 — Project 1: We previously developed a NHP ICU model in healthy (uninfected) NHPs. We have extended this model to included supportive care of animals infected with E.coli or K. pneumoniae. Among K. pneumoniae infected animals, we have completed initial bacterial dose-response studies and are now proc…
ROBERT A DAVEY · WASHINGTON UNIVERSITY · 2023 · $371,762 — Core C – Project Summary/Abstract Core C provides support for high biocontainment work to Research Projects 1 (RP01), RP02, RP03 and Core B. Work is prioritized through Core A. Core personnel bring unique expertise in molecular biology, cell biology and animal disease modeling for Ebola and Marburg …
Thomas William Geisbert · UNIVERSITY OF TEXAS MED BR GALVESTON · 2023 · $2,890,889 — PROJECT SUMMARY/ABSTRACT – BSL-4 Evaluation Core (Core B) Among viruses that cause disease in humans the filoviruses, Ebolavirus and Marburgvirus, stand out for their impressive lethality. These viruses are the most deadly human pathogens known to man with reported case fatality rates of up to 90%…
Gaya K. Amarasinghe · WASHINGTON UNIVERSITY · 2023 · $3,354,992 — Overall Project Summary/Abstract: Molecular mechanisms of filoviral-host interactions The family Filoviridae, which includes Ebola virus (EBOV) and Marburg virus (MARV), are zoonotic pathogens that cause outbreaks of severe human disease and require biosafety level 4 (BSL4) containment for study. Re…
Jay Kenneth Fisher · REDBUD LABS, INC. · 2023 · $983,642 — ABSTRACT We propose to develop a point-of-need system for differential molecular identification of filoviruses from syndromically similar infections. Our goal is to enable rapid, sensitive, and specific identification of quarantinable infections to reduce nosocomial risk and improve outbreak respons…
Junki Maruyama · UNIVERSITY OF TEXAS MED BR GALVESTON · 2023 · $249,000 — Lassa virus (LASV) is endemic in West African countries and causes outbreaks of LF annually. Although LASV is one of the most alarming pathogens from a public health perspective, there are few effective vaccines or therapeutics against LF. LASV must be handled at biosafety level 4 (BSL-4), due to …
Parizad Torabi-Parizi · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · 2023 · $108,714 — Coronavirus disease 19 (COVID-19) is a rapidly growing health threat in the United States with a fatality rate ten times greater than with seasonal influenza. The virus is highly transmissible and has rapidly infected large numbers of people in China, in several European countries, and now in the US…
Ferenc Livak · DIVISION OF BASIC SCIENCES - NCI · 2023 · $1,826,105 — The mission of the CCR LGI Flow Cytometry Core in Building 37 (FC37) is to offer up-to-date instrumentation and technical expertise to CCR investigators to assist cancer research. The core provides full-scale, state-of-the-art flow cytometry services including analytical sample acquisition, data ana…
Colleen B Jonsson · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · 2023 · $1,216,129 — PROJECT ABSTRACT The proposed Antiviral & Antimicrobial Countermeasures Discovery & Development Core (herein abbreviated as A2CD2C) will facilitate biomedical research targeted toward the discovery and/or development of countermeasures for prophylactic or therapeutic treatment of human biosafety le…
ELIZABETH ANN FITZPATRICK · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · 2023 · $744,995 — The University of Tennessee Health Science Center (UTHSC) Regional Biocontainment Laboratory (RBL) provides a vast array of services that support the discovery and development of countermeasures for biodefense and emerging infectious agents with unmet medical needs. Central to this mission is the su…
Thomas William Geisbert · UNIVERSITY OF TEXAS MED BR GALVESTON · 2023 · $2,317,735 — PROJECT 3 – ABSTRACT The goal of this project is to discover novel henipavirus inhibitors. Henipavirus is a deadly airborne respiratory pathogen that are under-researched and poorly understood. Antiviral therapy is urgently needed for henipaviruses for pandemic preparedness. We will achieve the goal…
BLANCA I RESTREPO · TEXAS BIOMEDICAL RESEARCH INSTITUTE · 2023 · $956,440 — ABSTRACT Tuberculosis (TB), caused by Mycobacterium tuberculosis (M.tb), is a leading infectious disease and cause of death worldwide. The growing burden of drug-resistant (DR)-TB is complicating TB treatment. Early diagnosis of TB with drug susceptibility testing (DST) is critical for successful tr…
Patricia Veronica Aguilar · UNIVERSITY OF TEXAS MED BR GALVESTON · 2023 · $297,402 — Abstract Non-malarial acute undifferentiated febrile illnesses (AUFIs) are significant causes of morbidity and mortality in Latin America, and the incidence of dengue-like illness has increased dramatically in recent years. As in most low-and middle-income countries, only a handful of “dengue” cases…
Yoshihiro Izumiya · UNIVERSITY OF CALIFORNIA AT DAVIS · 2023 · $529,822 — Deregulation of genome interactions through mutations at regulatory elements or mutation of responsible cellular nuclear enzymes result in multiple disorders. Although the significance of proper genomic-genomic interactions has been seen from disease phenotypes, the underlying molecular mechanisms o…
Craig A Fletcher · UNIV OF NORTH CAROLINA CHAPEL HILL · 2023 · $7,916,788 — PROJECT SUMMARY / ABSTRACT: The central goal of this project is to construct a 10,000 square feet biosafety level 3 (BSL3) research laboratory core facility to promote readiness to respond to future pandemics. Infectious diseases pose a severe and increasing threat to human health, especially in com…
Steven A. Ackerman · UNIVERSITY OF WISCONSIN-MADISON · 2023 · $348,296 — Project Summary/Abstract Using funding from two administrative supplements awarded by the NIH Office of Infrastructure Programs, the Wisconsin National Primate Research Center (WNPRC) contracted bioBubble, Inc. (Fort Collins, Colorado) to design, manufacture, and install soft-wall HEPA-filtered encl…
SUZETTE Alise PRIOLA · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2023 · $1,100,933 — Transmissible spongiform encephalopathies (TSEs or prion diseases) are a group of rare neurodegenerative diseases which include sporadic Creutzfeldt-Jakob disease (sCJD) in humans, scrapie in sheep, bovine spongiform encephalopathy (BSE), and chronic wasting disease (CWD) in mule deer and elk. Prion…
Alexander Bukreyev · UNIVERSITY OF TEXAS MED BR GALVESTON · 2023 · $83,092 — ADMINISTRATIVE CORE (Core A): PROJECT SUMMARY/ABSTRACT The Administrative Core is responsible for the strategic planning, overall management, and coordination of the Program Project (P01) “Molecular Mechanisms of the Dysregulated Immune Response to Ebola Virus”. It provides governance, financial ove…
STEPHEN C JAMESON · UNIVERSITY OF MINNESOTA · 2023 · $193,586 — Summary Core B NME Mouse Core Our published studies suggest that mice with more physiological exposure to natural mouse microbes have immune systems that are a better match for the immune system in humans: In contrast to typical “clean” laboratory mice (which are maintained in barrier facilities to …